Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2012092528) TREATMENT OF ERECTILE DYSFUNCTION AND OTHER INDICATIONS
Latest bibliographic data on file with the International Bureau   

Pub. No.: WO/2012/092528 International Application No.: PCT/US2011/067993
Publication Date: 05.07.2012 International Filing Date: 29.12.2011
IPC:
A61K 31/74 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
74
Synthetic polymeric materials
Applicants:
FOSSEL, Eric, T. [US/US]; US (UsOnly)
STRATEGIC SCIENCE & TECHNOLOGIES, LLC [US/US]; 58 Charles Street Cambridge, MA 02141, US (AllExceptUS)
Inventors:
FOSSEL, Eric, T.; US
Agent:
WALLER, Patrick, R.h.; Wolf, Greenfield & Sacks, P.C. 600 Atlantic Avenue Boston, MA 02210-2206, US
Priority Data:
61/427,99929.12.2010US
61/428,21329.12.2010US
Title (EN) TREATMENT OF ERECTILE DYSFUNCTION AND OTHER INDICATIONS
(FR) TRAITEMENT DE LA DYSÉRECTION ET AUTRES INDICATIONS
Abstract:
(EN) The present invention generally relates to the transdermal delivery of various compounds. In some aspects, transdermal delivery may be facilitated by the use of a hostile biophysical environment. One set of embodiments provides a composition for topical delivery comprising a phosphodiesterase type 5 inhibitor and/or a salt thereof, and optionally, a hostile biophysical environment and/or a nitric oxide donor. In some cases, the composition may be stabilized using a combination of a stabilization polymer (such as xanthan gum, KELTROL® BT and/or KELTROL® RD), propylene glycol, and a polysorbate surfactant such as Polysorbate 20, which combination unexpectedly provides temperature stability to the composition, e.g., at elevated temperatures such as at least 40 °C (at least about 104 °F), as compared to compositions lacking one or more of these.
(FR) L'invention concerne en général l'administration transdermique de divers composés. Selon certains aspects, l'administration transdermique peut être facilitée par l'utilisation d'un environnement biophysique hostile. Un ensemble de modes de réalisation divulguent une composition à administration locale, comprenant un inhibiteur de la photodiestérase de type 5 et/ou des sels de celui-ci, et éventuellement, un environnement biophysique hostile et/ou un donneur d'acide nitrique. Dans certains cas, la composition peut être stabilisée au moyen d'une combinaison de polymère de stabilisation (tel que la gomme de xanthane, le KELTROL® BT et/ou le KELTROL® RD), de propylène glycol, et d'un tensio-actif de polysorbate tel que le Polysorbate 20, ladite combinaison conférant, contre toute attente, une thermostabilité à la composition, par exemple à des températures élevées comme au moins 40°C (au moins environ 104°F), par rapport à une composition ne comprenant pas un ou plusieurs de ces éléments.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)